J. Moran

Abstract IA010: On the right TRACK: Operationalizing a national, patient-driven, decentralized trial offering comprehensive genomic profiling and a molecular tumor board for rare cancers

Collectively, rare cancers account for approximately 20–25% of all malignancies, and the challenges faced by patients and researchers are consistent across all rare cancer tumor types. Notably, patients encounter challenges in access to clinical trials, access to biomarker testing, and access to expert interpretation...